Trace Biosciences

Executive Summary

Trace Biosciences, founded in 2021 and based in Boston, is a pre-clinical biotechnology company developing targeted imaging agents for real-time nerve visualization during surgery. Its lead product, Nerve Trace, aims to prevent surgical nerve damage by integrating with existing clinical imaging systems to improve surgical precision. The company operates at the intersection of diagnostics and infectious disease, though its core focus remains on intraoperative nerve imaging. With a strong scientific premise and a clear unmet need in surgical safety, Trace Biosciences is positioned to address a significant market opportunity. However, as a pre-clinical company, it faces substantial technical and regulatory hurdles before commercialization.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Nerve Trace40% success
• Q4 2026First-in-Human Study Initiation35% success
• Q2 2026Strategic Partnership or Grant Award50% success